NYSE: ABTABBOTT LABORATORIES Stock
$109.45+3.24 (+3.05%)
Updated Jun 24, 2022
ABT Price
$109.45
Fair Value Price
N/A
Market Cap
$191.64B
52 Week Low
$101.24
52 Week High
$142.60
P/E
25.16x
P/B
5.38x
P/S
4.69x
PEG
4.3x
Dividend Yield
1.68%
Revenue
$44.51B
Earnings
$7.73B
Gross Margin
57%
Operating Margin
21.51%
Profit Margin
17.4%
Debt to Equity
1.08
Operating Cash Flow
$10B
Beta
0.87
Next Earnings
Jul 20, 2022
Ex-Dividend
Jul 14, 2022
Next Dividend
Aug 15, 2022
Zen Score
–
Industry Average (35)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABT ($109.45) is trading above its intrinsic value of $106.58, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABT is poor value based on its earnings relative to its share price (25.16x), compared to the US market average (20.48x)
P/E vs Market Valuation
ABT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ABT due diligence checks available for Premium users.
ABT News
Valuation
ABT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
25.16x
Industry
15.26x
Market
20.48x
ABT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.38x
Industry
3.76x
ABT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABT price to earnings growth (PEG)
For valuing profitable companies with growth potential
ABT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ABT's financial health
Profit margin
Revenue
$11.9B
Net Income
$2.4B
Profit Margin
20.6%
ABT's Earnings (EBIT) of $9.57B... subscribe to Premium to read more.
Interest Coverage Financials
ABT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$74.0B
Liabilities
$38.4B
Debt to equity
1.08
ABT's short-term assets ($23.43B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABT's long-term liabilities ($25.73B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.1B
Investing
-$360.0M
Financing
-$3.8B
ABT's operating cash flow ($9.96B)... subscribe to Premium to read more.
Debt Coverage Financials
ABT vs Medical Device Stocks
ABBOTT LABORATORIES Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.